### General description

**INN** | Methotrexate  
---|---  
**ATC codes** | L01BA01 L04AX03  
**Medicine type** | Chemical agent  
**EML status history** |  
First added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites  
Added in 1997 (TRS 882) for Rheumatoid arthritis, serology unspecified  
Added in 2015 (TRS 994) for Malignant neoplasms of breast  
Added in 2015 (TRS 994) for Malignant trophoblastic neoplasms of placenta  
Added in 2015 (TRS 994) for Lymphoid leukaemia, not elsewhere classified  
Added in 2015 (TRS 994) for Osteosarcoma of bone and articular cartilage of unspecified sites  
Added in 2015 (TRS 994) for Acute myeloid leukaemia with recurrent genetic abnormalities  
Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites

### Recommendations

#### Section: Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)  
- Oral > Solid: 2.5 mg (as sodium salt)

#### Indications

- **Malignant neoplasms of breast**  
- **Malignant trophoblastic neoplasms of placenta**  
- **Osteosarcoma of bone and articular cartilage of unspecified sites**  
- **Lymphoid leukaemia, not elsewhere classified**  
- **Acute myeloid leukaemia with recurrent genetic abnormalities**  
- **Unspecified malignant neoplasms of ill-defined or unspecified sites**
### Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 2.5 mg (as sodium salt)

**Indications**

- Rheumatoid arthritis, serology unspecified